Presentation Highlights Ziopharm’s Suite of Cellular Therapy Technologies BOSTON , April 28, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today that Laurence J.N. Cooper , PhD, MD, Scientific Advisor to the Company, was the inaugural
BOSTON and HOUSTON and TAIPEI, Taiwan , April 19, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today that in March, the first patient was infused in the CD19-Specific Rapid Personalized Manufacturing (“RPM”) CAR-T Phase I Trial, being
Adds to growing body of published research supporting the development of non-viral TCR-T therapies for the treatment of epithelial cancers BOSTON and HOUSTON , April 07, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today it will be
Heidi Hagen Appointed Interim Chief Executive Officer Replacing Dr. Laurence Cooper ; Search for Permanent CEO Initiated Dr. Laurence Cooper Expected to Continue with Company in a Scientific Advisory Role James Huang Appointed Executive Chairman and Board Refreshment Completed FDA IND Clearance
Company to Hold R&D Day on Thursday, March 11, 2021 BOSTON , Feb. 16, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (the “Company”) (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast to discuss financial results for the fourth quarter and full year 2020 on
BOSTON , Feb. 05, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced the election of Robert Postma to its Board of Directors (the “Board”), effective immediately. Mr. Postma is the Founder of WaterMill Asset Management, a sizeable and
– Mr. Huang is a veteran industry entrepreneur with 20+ years founding and funding biotech innovation – – Heidi Hagen elected Lead Independent Director – BOSTON , Jan. 14, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP) today announced the election of
BOSTON , Dec. 23, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the H.C.
– Advances Eden BioCell’s clinical program to validate Rapid Personalized Manufacturing (RPM) – – Clinical trial to study autologous CD19-specific CAR-T using RPM technology designed to reduce cost and simplify production for infusion the day after gene transfer – BOSTON , Dec.
Jaime Vieser and Holger Weis Elected to Board of Directors BOSTON , Dec. 16, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today issued a statement in connection with the consent solicitation (the “Consent Solicitation”) initiated by WaterMill Asset